


FORM PTO-1449

U.S. Dept. of Commerce

Patent and Trademark Office

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)



Atty Docket No.

P1712R1-1D1

Serial No.

10/028,410

Applicant

Dubaquie et al.

Filing Date

19 Dec 2001

Group

Unknown 1647

PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
*	1	5,077,276	31.12.91	Ballard, F. et al.			
*	2	5,106,832	21.04.92	Froesch et al.			
*	3	5,164,370	17.11.92	Ballard, F. et al.			
*	4	5,273,961	28.12.93	Clark			
*	5	5,470,828	28.11.95	Ballard et al.			
*	6	5,514,646	07.05.96	Chance et al.			
*	7	5,565,428	15.10.96	Clark et al.			
*	8	5,714,460	03.02.98	Gluckman et al.			
*	9	5,741,776	21.04.98	Clark et al.			
*	10	5,750,373	12.05.98	Garrard et al.			
*	11	5,821,047	13.10.98	Garrard et al.			
*	12	5,834,250	10.11.98	Wells et al.			
*	13	5,891,722	06.04.99	Fuks et al.			
*	14	5,985,830	16.11.99	Acott et al.			
*	15	5,994,303	30.11.99	Arrhenius-Nyberg et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
*	16	214,826	18.03.87	EPO				
*	17	742,228	13.11.96	EPO				
*	18	965,596	22.12.99	EPO				
*	19	WO 00/20023	13.04.00	PCT				
*	20	WO 00/23469	27.04.00	PCT				
*	21	WO 89/05822	29.06.89	PCT				
*	22	WO 94/04569	03.03.94	PCT				
*	23	WO 96/33216	24.10.96	PCT				
*	24	WO 97/39032	23.10.97	PCT				
*	25	WO 98/45427	15.10.98	PCT				
*	26	WO 98/56406	17.12.98	PCT				
*	27	WO 99/32620	01.07.99	PCT (TRANSLATION ATTACHED)				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*	28	Bach and Rechler, "Insulin-like Growth Factor Binding Proteins" <i>Diabetes Reviews</i> 3:38-61 (1995)
*	29	Bagley et al., "A key functional role for the insulin-like growth factor 1 N-terminal pentapeptide" <i>Biochemical Journal</i> 259(3):665-671 (May 1, 1989)
*	30	Bar et al., "Tissue localization of perfused endothelial cell IGF binding protein is markedly altered by association with IGF-I" <i>Endocrinology</i> 127(6):3243-3245 (1990)

Examiner *Brigitte C. Bunner* Date Considered *7/7/03*

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DUPPLICATE

FORM PTO-1449

U.S. Dept. of Commerce

Patent and Trademark Office

Atty Docket No.

P1712R1-1D1

Serial No.

10/028,410

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

APR 11 2002

Applicant

Dubaquie et al.

Filing Date

19 Dec 2001

Group

Unknown 1647

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

* 31	Baron et al., "Dexamethasone acts locally to inhibit longitudinal bone growth in rabbits" <u>American Journal of Physiology</u> 263(3 Pt 1):E489-E492 (Sep 1992)
* 32	Barreca et al., "Short stature associated with high circulating insulin-like growth factor (IGF)-binding protein-1 and low circulating IGF-II: effect of growth hormone therapy" <u>Journal of Clinical Endocrinology & Metabolism</u> 83(10):3534-3541 (Oct 1998)
* 33	Batch et al., "Abnormal regulation of insulin-like growth factor binding proteins in adolescents with insulin-dependent diabetes" <u>Journal of Clinical Endocrinology & Metabolism</u> 73(5):964-968 (Nov 1991)
* 34	Baxter et al., "Recommendations for nomenclature of the insulin-like growth factor binding protein superfamily" <u>Endocrinology</u> 139(10):4036 (Oct 1998)
* 35	Baxter et al., "Structural determinants for binary and ternary complex formation between insulin-like growth factor-I (IGF-I) and IGF binding protein-3" <u>Journal of Biological Chemistry</u> 267(1):60-65 (Jan 5, 1992)
* 36	Bayne et al., "Structural analogs of human insulin-like growth factor I with reduced affinity for serum binding proteins and the type 2 insulin-like growth factor receptor" <u>Journal of Biological Chemistry</u> 263:6233-6239 (1988)
* 37	Bayne et al., "The C region of human insulin-like growth factor (IGF) I is required for high affinity binding to the type 1 IGF receptor" <u>Journal of Biological Chemistry</u> 264(19):11004-11008 (1988)
* 38	Bayne et al., "The roles of tyrosines 24, 31, and 60 in the high affinity binding of insulin-like growth factor-I to the type I insulin-like growth factor receptor" <u>Journal of Biological Chemistry</u> 265(26):15648-15652 (Sep 15, 1990)
* 39	Bereket et al., "Insulin treatment normalizes reduced free insulin-like growth factor-I concentrations in diabetic children" <u>Clinical Endocrinology</u> 45(3):321-326 (Sep 1996)
* 40	Bereket et al., "Regulation of the insulin-like growth factor system by acute acidosis" <u>Endocrinology</u> 137(6):2238-2245 (Jun 1996)
* 41	Blum et al., "Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uremia" <u>Pediatric Nephrology</u> 5(4):539-544 (Jul 1991)
* 42	Blum, W., "Insulin-like growth factors (IGFs) and IGF binding proteins in chronic renal failure: evidence for reduced secretion of IGFs" <u>Acta Paediatr. Scand.</u> 379(Suppl):24-31 (1991)
* 43	Bogdan and Thorn, "Anatomy of hot spots in protein interfaces" <u>Journal of Molecular Biology</u> 280(1):1-9 (Jul 3, 1998)
* 44	Brems et al., "Altering the association properties of insulin by amino acid replacement" <u>Protein Engineering</u> 5(6):527-533 (1992)
* 45	Cascieri et al., "Mutants of human insulin-like growth factor I with reduced affinity for the type 1 insulin-like growth factor receptor" <u>Biochemistry</u> 27(9):3229-3233 (May 3, 1988)
* 46	Cascieri et al., "Structural analogs of human insulin-like growth factor (IGF) I with altered affinity for type 2 IGF receptors" <u>Journal of Biological Chemistry</u> 264:2199-2202 (1989)
* 47	Chernausek et al., "Proteolytic cleavage of insulin-like growth factor binding protein 4 (IGFBP-4). Localization of cleavage site to non-homologous region of native IGFBP-4" <u>Journal of Biological Chemistry</u> 270(19):11377-11382 (May 12, 1995)
* 48	Clark and Robinson, "Up and down the growth hormone cascade" <u>Cytokine & Growth Factor Reviews</u> 7(1):65-80 (Jun 1996)
* 49	Clemmons et al., "Competition for binding to insulin-like growth factor (IGF) binding protein-2, 3, 4, and 5 by the IGFs and IGF analogs" <u>Endocrinology</u> 131(2):890-895 (Aug 1992)
* 50	Clemmons et al., "Discrete Alterations of the Insulin-like Growth Factor I Molecule Which Alter Its Affinity for Insulin-like Growth Factor-binding Proteins Result in Changes in Bioactivity" <u>Journal of Biological Chemistry</u> 265(21):12210-12216 (1990)

Examiner

Bridget C. Burner

Date Considered

7/7/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DUPLICATE

FORM PTO-1449

U.S. Dept. of Commerce

Patent and Trademark Office

Atty Docket No.


P1712R1-1D1

Serial No.

10/028,410

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)



Applicant

Dubaquie et al.

Filing Date

19 Dec 2001

Group

Unknown 1647

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

* 51	Clemmons, D., "Insulin-like growth factor binding proteins and their role in controlling IGF actions" <u>Cytokine & Growth Factor Reviews</u> 8(1):45-62 (Mar 1997)
* 52	Cohick and Clemons, "The insulin-like growth factors" <u>Annu. Rev. Physiol.</u> 55:131-153 (1993)
* 53	Conover, "Potentiation of insulin-like growth factor (IGF) action by IGF-binding protein-3: studies of underlying mechanism" <u>Endocrinology</u> 130(6):3191-3199 (Apr 1992)
* 54	Conover, C., "Insulin-like growth factor binding protein proteolysis in bone cell models" <u>Progress in Growth Factor Research</u> 6(2-4):301-309 (1995)
* 55	Cooke et al., "Solution Structure of Human Insulin-Like Growth Factor 1: A Nuclear Magnetic Resonance and Restrained Molecular Dynamics Study" <u>Biochemistry</u> 30:5484-5491 (1991)
* 56	Cox et al., "Recombinant human insulin-like growth factor (IGF)-binding protein-1 inhibits somatic growth stimulated by IGF-I and growth hormone in hypophysectomized rats" <u>Endocrinology</u> 135(5):1913-1920 (1994)
* 57	Crown and Holly, "The insulin-like growth factor system in critical illness: pathophysiology and therapeutic potential" <u>Clinical Nutrition</u> 14:321-328 (1995)
* 58	Cunningham and Wells, "Comparison of a structural and a functional epitope" <u>Journal of Molecular Biology</u> 234(3):554-563 (Dec 5, 1993)
* 59	Cunningham and Wells, "High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis" <u>Science</u> 244:1081-1085 (1989)
* 60	Cunningham et al., "Production of an Atrial Natriuretic Peptide Variant that is Specific for Type A Receptor" <u>EMBO Journal</u> 13(11):2508-2515 (1994)
* 61	Davidson, M., "Effect of growth hormone on carbohydrate and lipid metabolism" <u>Endocrine Reviews</u> 8(2):115-131 (May 1987)
* 62	DeWolf et al., "Solution structure of a mini IGF-1" <u>Protein Science</u> 5(11):2193-2202 (Nov 1996)
* 63	Dubaquie and Lowman, "Total Alanine-Scanning Mutagenesis of Insulin-Like Growth Factor I (IGF-I) Identifies Differential Binding Epitopes for IGFBP-1 and IGFBP-3" <u>Biochemistry</u> 38(20):6386-6396 (1999)
* 64	Fuller et al., "Stimulation of Cardiac Protein Synthesis by Insulin-like Growth Factors" <u>Biochemical Society Transactions</u> 19:277S (1991)
* 65	Garrett et al., "Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor" <u>Nature</u> 394(6691):395-399 (Jul 23, 1998)
* 66	Guler et al., "Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects" <u>Proc. Natl. Acad. Sci. USA</u> 86:2868-2872 (April 1989)
* 67	Guler et al., "Insulin-like growth factor I increases glomerular filtration rate and renal plasma flow in man" <u>Acta Endocrinologica</u> 121:101-106 (1989)
* 68	Hall et al., "Serum levels of the low molecular weight form of insulin-like growth factor binding protein in healthy subjects and patients with growth hormone deficiency, acromegaly and anorexia nervosa" <u>Acta Endocrinologica</u> 118(3):321-326 (Jul 1988)
* 69	Hamerman and Miller, "The growth hormone insulin-like factor axis in kidney revisited" <u>Am. J. Physiol.</u> 265:F1-F14 (1993)
* 70	Hamerman and Miller, "Therapeutic use of growth factors in renal failure" <u>J. Am. Soc. Nephrol.</u> 5:1-11 (1994)

Examiner

Bridget E. Bunner


Date Considered

7/7/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DUPLICATE

FORM PTO-1449



Atty Docket No.

P1712R1-1D1

Serial No.

10/028,410

Applicant

Dubaquie et al.

Filing Date

19 Dec 2001

Group

Unknown 1647

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

* 71	Heding et al., "Biosensor measurement of the binding of insulin-like growth factors I and II and their analogues to the insulin-like growth factor-binding protein-3" <u>Journal of Biological Chemistry</u> 271(24):13948-13952 (Jun 14, 1996)
* 72	Hirschberg et al., "Effects of insulin-like growth factor I on renal function in normal men" <u>Kidney International</u> 43:387-397 (1993)
* 73	Hise et al., "Influence of circulating insulin-like growth factor-I compared with that of intrarenal insulin-like growth factor-I on proximal nephron receptor density in rats" <u>Clinical Science</u> 83:233-239 (1992)
* 74	Hoogenberg et al., "Effect of growth hormone and insulin-like growth factor I on urinary albumin excretion: studies in acromegaly and growth hormone deficiency" <u>Acta Endocrinologica</u> 129:151-157 (1993)
* 75	Horber et al., "Differential effects of prednisone and growth hormone on fuel metabolism and insulin antagonism in humans" <u>Diabetes</u> 40(1):141-149 (Jan 1991)
* 76	Hua et al., "Native and non-native structure in a protein-folding intermediate: spectroscopic studies of partially reduced IGF-I and an engineered alanine model" <u>Journal of Molecular Biology</u> 259(2):297-313 (Jun 7, 1996)
* 77	Ikkos et al., "Glomerular filtration rate and renal plasma flow in acromegaly" <u>Acta Endocrinologica</u> 21:226-236 (1956)
* 78	Jansson et al., "Structural Changes in Insulin-Like Growth Factor (IGF) I Mutant Proteins Affecting Binding Kinetic Rates to IGF Binding Protein 1 and IGF-I Receptor" <u>Biochemistry</u> 36:4108-4117 (1997)
* 79	Jansson et al., "The Insulin-Like Growth Factor (IGF) Binding Protein 1 Binding Epitope on IGF-I Probed by Heteronuclear NMR Spectroscopy and Mutational Analysis" <u>The Journal of Biological Chemistry</u> 273(38):24701-24707 (September 18, 1998)
* 80	Joly et al., "Overexpression of Escherichia coli Oxidoreductases Increases Recombinant Insulin-Like Growth Factor-I Accumulation." <u>Proc. Natl. Acad. Sci. USA</u> 95:2773-2777 (Mar 1998)
* 81	Jones et al., "Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions" <u>Endocrine Reviews</u> 16(1):3-34 (1995)
* 82	Kalus et al., "Structure of the IGF-binding domain of the insulin-like growth factor-binding protein-5 (IGFBP-5): implications for IGF and IGF-I receptor interactions" <u>EMBO Journal</u> 17(22):6558-6572 (Nov 16, 1998)
* 83	Kanety et al., "Long-term treatment of Laron type dwarfs with insulin-like growth factor-I increases serum insulin-like growth factor-binding protein-3 in the absence of growth hormone activity" <u>Acta Endocrinologica</u> 128(2):144-149 (Feb 1993)
* 84	King et al., "Production and characterization of recombinant insulin-like growth factor-I (IGF-I) and potent analogues of IGF-I, with Gly or Arg substituted for Glu ³ , following their expression in Escherichia coli as fusion proteins" <u>Journal of Molecular Endocrinology</u> 8(1):29-41 (Feb 1992)
* 85	Kristensen, C. et al., "Alanine Scanning Mutagenesis of Insulin" <u>The Journal of Biological Chemistry</u> 272(20):12978-12983 (May 16, 1997)
* 86	Kupfer et al., "Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously" <u>J. Clin. Invest.</u> 91:391-396 (1993)
* 87	Lee et al., "IGF binding proteins in growth-retarded children with chronic renal failure" <u>Pediatric Research</u> 26(4):308-315 (Oct 1989)
* 88	Lee et al., "Insulin-Like Growth Factor (IGF) Binding Protein Complementary Deoxyribonucleic Acid from Human HEP G2 Hepatoma Cells: Predicted Protein Sequence Suggests an IGF Binding Domain Different from Those of the IGF-I and IGF-II Receptors" <u>Mol. Endocrinol.</u> 2(5):404-411 (1988)
* 89	Lee et al., "Insulin-like growth factor binding protein-1: recent findings and new directions" <u>Proceedings of the Society for Experimental Biology & Medicine</u> 216(3):319-357 (Dec 1997)
* 90	Lewitt et al., "Bioavailability of insulin-like growth factors (IGFs) in rats determined by the molecular distribution of human IGF-binding protein-3" <u>Endocrinology</u> 133:1797-1802 (1993)

Examiner

Bridget C. Brunner

Date Considered

7/7/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


D U P L I C A T E

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P1712R1-1D1Serial No.
10/028,410

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)



Patent and Trademark Office

Applicant
Dubaquie et al.Filing Date
19 Dec 2001Group
Unknown 1647

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

* 91	Lewitt et al., "Insulin-like Growth Factor-binding Protein-1 Modulates Blood Glucose Levels" <u>Endocrinology</u> 129(4):2254-2256 (1991)
* 92	Liu et al., "Characterization of insulin-like growth factor-binding proteins in human serum from patients with chronic renal failure" <u>Journal of Clinical Endocrinology & Metabolism</u> 70(3):620-628 (Mar 1990)
* 93	Loddick et al., "Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke" <u>Proc. Natl. Acad. Sci. USA</u> 95(4):1894-1898 (Feb 17, 1998)
* 94	Lowman and Wells, "Affinity maturation of human growth hormone by monovalent phage display" <u>Journal of Molecular Biology</u> 234(3):564-578 (1993)
* 95	Lowman et al., "Molecular mimics of insulin-like growth factor 1 (IGF-1) for inhibiting IGF-1: IGF-binding protein interactions" <u>Biochemistry</u> 37(25):8870-8878 (1998)
* 96	Lowman, H., "Phage display of peptide libraries on protein scaffolds" <u>Methods in Molecular Biology</u> , Chapter 24, 87:249-264 (1998)
* 97	Magee et al., "Insulin-like growth factor I and its binding proteins: a study of the binding interface using B-domain analogues" <u>Biochemistry</u> 38(48):15863-15870 (Nov 30, 1999)
* 98	Manes et al., "Functional epitope mapping of insulin-like growth factor I (IGF-I) by Anti-IGF-I monoclonal antibodies" <u>Endocrinology</u> 138(3):905-915 (1997)
* 99	Martin and Baxter, "Regulation and actions of the insulin-like growth factor binding proteins" <u>Current Opinion in Endocrinology and Diabetes</u> pps. 16-21 (1994)
*100	McCarthy et al., "Cortisol inhibits the synthesis of insulin-like growth factor-I in skeletal cells" <u>Endocrinology</u> 126(3):1569-1575 (Mar 1990)
*101	McInnes and Sykes, "Growth factor receptors: structure, mechanism, and drug discovery" <u>Biopolymers</u> 43(5):339-366 (1997)
*102	Miller et al., "Effects of IGF-I on renal function in end-stage chronic renal failure" <u>Kidney International</u> 46:201-207 (1994)
*103	Moses, A., "Recombinant insulin-like growth factor-I as therapy in states of altered carbohydrate homeostasis" <u>Current Opinion in Endocrinology and Diabetes</u> 4:16-25 (1997)
*104	Murphy et al., "Phenotypic manifestations of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-3 overexpression in transgenic mice" <u>Progress in Growth Factor Research</u> 6(2-4):425-432 (s 1995)
*105	Nakagawa, S. et al., "Role of the Phenylalanine B25 Side Chain in Directing Insulin Interaction with Its Receptor" <u>The Journal of Biological Chemistry</u> 261(16):7332-7341 (June 5, 1986)
*106	O'Shea and Layish, "Growth hormone and the kidney: a case presentation and review of the literature" <u>J. Am. Soc. Nephrol.</u> 3:157-161 (1992)
*107	O'Shea et al., "Effects of IGF-I on renal function in patients with chronic renal failure" <u>Am. J. Physiol.</u> 264:F917-F922 (1993)
*108	Oh et al., "Characterization of the affinities of insulin-like growth factor (IGF)-binding proteins 1-4 for IGF-I, IGF-II, IGF-I/insulin hybrid, and IGF-I analogs" <u>Endocrinology</u> 132:1337-1344 (1993)
*109	Peterkofsky et al., "Elevated Activity of Low Molecular Weight Insulin-Like Growth Factor-Binding Proteins in Sera of Vitamin C-Deficient and Fasted Guinea Pigs" <u>Endocrinology</u> 128(4):1769-1779 (1991)
*110	Powell et al., "Characterization of insulin-like growth factor binding protein-3 in chronic renal failure serum" <u>Pediatric Research</u> 33(2):136-143 (Feb 1993)

Examiner

Brigitte C. Bunner

Date Considered

7/7/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DUPLICATE

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1712R1-1D1

Serial No.

10/028,410

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Dubaquie et al.

Filing Date

19 Dec 2001

Group

Unknown 1647

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*111	Powell et al., "Modulation of growth factors by growth hormone in children with chronic renal failure." <u>Kidney International</u> 51(6):1970-1979 (Jun 1997)
*112	Powell et al., "Serum concentrations of insulin-like growth factor (IGF)-1, IGF-2 and unsaturated somatomedin carrier proteins in children with chronic renal failure" <u>American Journal of Kidney Diseases</u> 10(4):287-292 (Oct 1987)
*113	Quigley and Baum, "Effects of growth hormone and insulin-like growth factor I on rabbit proximal convoluted tubule transport" <u>J. Clin. Invest.</u> 88:368-374 (1991)
*114	Rajkumar et al., "Growth retardation and hyperglycemia in insulin-like growth factor binding protein-1 transgenic mice" <u>Endocrinology</u> 136(9):4029-4034 (Sep 1995)
*115	Rosenfeld et al., "IGF-1 treatment of syndromes of growth hormone insensitivity" <u>The insulin-like growth factors and their regulatory proteins</u> , Baxter et al. eds., Amsterdam:Excerpta Medica pps. 457-463 (1994)
*116	Ross et al., "Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I" <u>Clinical Endocrinology</u> 95(1):47-54 (Jul 1991)
*117	Sapir et al., "The role of alanine and glutamine in steroid-induced nitrogen wasting in man" <u>Clinical Science & Molecular Medicine</u> 53(3):215-220 (Sep 1977)
*118	Scharf et al., "Insulin-like growth factor-I serum concentrations and patterns of insulin-like growth factor binding proteins in patients with chronic liver disease" <u>Journal of Hepatology</u> 25(5):689-699 (Nov 1996)
*119	Shmueli et al., "High insulin-like growth factor binding protein 1 levels in cirrhosis: link with insulin resistance" <u>Hepatology</u> 24(1):127-133 (Jul 1996)
*120	Simmons et al., "Increased proteolysis. An effect of increases in plasma cortisol within the physiologic range" <u>Journal of Clinical Investigation</u> 73(2):412-420 (Feb 1984)
*121	Simpson et al., "Insulin-like growth factor-I and diabetes. A review" <u>Growth Hormone and IGF Research</u> 8:83-95 (1998)
*122	Slieker et al., "Insulin and IGF-I Analogs: Novel Approaches to Improved Insulin Pharmacokinetics" <u>Adv. Experimental Med. Biol.</u> 343:25-32 (1994)
*123	Terasawa et al., "Solution structure of human insulin-like growth factor II; recognition sites for receptors and binding proteins" <u>EMBO Journal</u> 13(23):5590-5597 (Dec 1, 1994)
*124	Thrailkill et al., "Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system" <u>Journal of Clin. Endocrinol. & Metab.</u> 82(4):1181-1187 (Apr 1997)
*125	Tomas et al., "Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats" <u>Biochemical Journal</u> 282(Pt 1):91-97 (Feb 15, 1992)
*126	Tonshoff et al., "Decreased hepatic insulin-like growth factor (IGF)-I and increased IGF binding protein-1 and -2 gene expression in experimental uremia" <u>Endocrinology</u> 138(3):938-946 (Mar 1997)
*127	Tonshoff et al., "Insulin-like growth factors (IGF) and IGF binding proteins in children with chronic renal failure" <u>Progress in Growth Factor Research</u> 6(2-4):481-491 (1995)
*128	Tonshoff et al., "Serum insulin-like growth factors (IGFs) and IGF binding proteins 1, 2, and 3 in children with chronic renal failure: relationship to height and glomerular filtration rate" <u>Journal of Clinical Endocrinology & Metabolism</u> 80(9):2684-2691 (Sep 1995)
*129	Tonshoff et al., "Serum insulin-like growth factors and their binding proteins in children with end-stage renal disease" <u>Pediatric Nephrology</u> 10(3):269-274 (Jun 1996)
*130	Torres et al., "Solution structure of human insulin-like growth factor II. Relationship to receptor and binding protein interactions" <u>Journal of Molecular Biology</u> 248(2):385-401 (Apr 28, 1995)

Examiner

Budget C. Bunne

Date Considered

7/7/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

D U P L I C A T E

FORM PTO-1449	ORIGINALLY FILED U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1712R1-1D1	Serial No. 10/028,410
LIST OF DISCLOSURES CITED BY APPLICANT APR 11 2002 (Use several sheets if necessary)		Applicant Dubaquie et al.	
		Filing Date 19 Dec 2001	Group Unknown 1647

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- | | |
|------|--|
| *131 | Trainer et al., "Pyridostigmine partially reverses dexamethasone-induced inhibition of the growth hormone response to growth hormone-releasing hormone" <u>Journal of Endocrinology</u> 134(3):513-517 (Sep 1992) |
| *132 | Ullrich et al., "Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity" <u>EMBO Journal</u> 5(10):2503-2512 (1986) |
| *133 | Umpleby et al., "Effects of Insulin-like Growth Factor-I (IGF-I), Insulin and Combined IGF-I-insulin Infusions on Protein Metabolism in Dogs" <u>Eur. J. Clin. Invest.</u> 24:337-344 (1994) |
| *134 | Underwood et al., "IGFs: Function and Clinical Importance 6 Therapy With Recombinant Human Insulin-like Growth Factor I in Children With Insensitivity to Growth Hormone and in catabolic conditions" <u>J. Internal Med.</u> 234:571-577 (1993) |
| *135 | Walker et al., "Stimulation of statural growth by recombinant insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron type)" <u>J. Pediatr.</u> 121:641-646 (1992) |
| *136 | Wells, J. A., "Additivity of Mutational Effects in Proteins" <u>Biochemistry</u> 29(37):8509-8517 (Sep 18, 1990) |
| *137 | Wolfson et al., "Insulin to inhibit protein catabolism after injury" <u>New England J. of Medicine</u> 300(1):14-17 (Jan 4, 1979) |

Examiner Bridget C. Bunner

Date Considered

7/7/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

D U P L I C A T E